Shortened Aggrastat® Versus Integrilin in Percutaneous Coronary Intervention

Summary

The purpose this study is to assess whether a tirofiban regimen of a high-dose bolus plus a shortened infusion duration compared to label-dosing eptifibatide in patients undergoing percutaneous coronary intervention (PCI) is associated with a non-inferior composite rate of death, PCI-related myocardial infarction, urgent target vessel revascularization or in-hospital major bleeding within 48 hours following PCI or hospital discharge, whichever comes first.

Timeline

Start

2012-04

Primary completion

2018-12

Completion

2019-03

Outcome

Met primary endpoint

release “Medicure Announces that the Shortened AGGRASTAT® Versus INTEGRILIN® in Percutaneous Coronary Intervention (SAVI-PCI) Study has Met its Primary Endpoint” medicure.com ↗

Drugs

Indications